- Made Scientific has entered into a manufacturing partnership with Hemogenyx Pharmaceuticals to advance HG-CT-1, a CAR-T therapy for relapsed/refractory acute myeloid leukaemia (AML).
- The agreement covers technology transfer and manufacturing at Made Scientific’s GMP facilities in New Jersey.
Made Scientific, a U.S.-based CDMO, has partnered with Hemogenyx Pharmaceuticals to support the development and manufacturing of HG-CT-1, the company’s lead CAR-T therapy. The programme is being evaluated in a Phase I clinical trial for adult patients with relapsed/refractory AML.
The partnership will leverage Made Scientific’s expertise in CAR-T technology transfer and its GMP facilities in Newark and Princeton, New Jersey, which are equipped for both clinical and commercial manufacturing. The collaboration also has the potential to extend support for additional trial cohorts involving paediatric AML patients.
Hemogenyx has reported progress in its Phase I study, with early clinical data supporting confidence in the safety and potential efficacy of HG-CT-1. Dr. Vladislav Sandler, CEO and Co-Founder of Hemogenyx, said: “Partnering with a trusted CDMO like Made Scientific is essential to the success of HG-CT-1, our lead CAR-T therapy. Made’s expertise in cell therapy manufacturing will be instrumental in driving the continued progress of this potential breakthrough therapy for patients with relapsed or refractory AML.”
Made Scientific’s Chairman and CEO, Syed T. Husain, stated that the collaboration reflects the company’s commitment to advancing next-generation cell therapies through its integrated development and contract manufacturing services.
